Authors
Latest:
Tropomyosin-Related Kinases (TRK) Making Headway in Head and Neck CancerTreatment of certain head and neck cancers may soon be fundamentally transformed through the use of molecular diagnostics to dissect essential oncogenic driver pathways, and ultimately to identify targeted therapies that specifically inhibit them.
Latest:
Exploring the Future of CAR T-Cell Therapy in Multiple MyelomaC. Ola Landgren, MD, PhD, discusses what is next for chimeric antigen receptor T-cell therapy in the multiple myeloma landscape.
Latest:
New Options Possible in Patients With NSCLC and Brain MetastasesA study published in the Journal of Clinical Oncology found that an EGFR inhibitor, erlotinib, was well tolerated in combination with whole-brain radiation therapy for patients with brain metastases from NSCLC.
Latest:
The Design of a Chimeric Antigen ReceptorCameron J. Turtle, MD, PhD, from the Fred Hutchinson Cancer Research Center, discusses the design of a chimeric antigen receptor (CAR).
Latest:
The Relationship Between CAR-Modified CD4 and CD8 T Cells in B-Cell MalignanciesCameron J. Turtle, MD, PhD, discuses the relationship between CD4 and CD8 T cells in patients with B-cell malignancies.
Latest:
Dr. Carey Anders on Exclusion of Patients With Brain Metastases From Clinical TrialsCarey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, UNC Chapel Hill, discusses the exclusion of patients with breast cancer who have developed brain metastases from clinical trials.
Latest:
Analyzing Challenges in Treating Patients With Relapsed/Refractory Follicular LymphomaCarla Casulo, MD, discusses the challenges surrounding the treatment of patients with relapsed/refractory follicular lymphoma.
Latest:
Comparing Data for Capecitabine After Neoadjuvant Chemotherapy in TNBCCarlos L. Arteaga, MD, discusses the use of capecitabine after neoadjuvant chemotherapy in patients with triple-negative breast cancer.
Latest:
Using the Angiogenesis Inhibitor Pazopanib to Treat Ovarian CancerCarol Aghajanian, MD, from the Memorial Sloan-Kettering Cancer Center, discusses a phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Latest:
The Role of Oncology Nurse Navigators in Healthcare ReformCarol Bush, BS, RN, discusses the role of oncology nurse navigators in healthcare reform.
Latest:
OS Results of a Study Evaluating Dabrafenib and Trametinib in MelanomaCaroline Robert, MD, PhD, head of the Dermatology Unit at the Institut Gustave-Roussy in Paris, discusses overall survival (OS) results of a recent study evaluating dabrafenib and trametinib in melanoma.
Latest:
Elacestrant Shows Superior PFS vs SOC in EMERALD Subgroup AnalysisElacestrant prolonged progression-free survival in patients with pretreated, ER-positive, HER2-negative breast cancer.
Latest:
The Diagnosis of Thyroid CancerCarrie C. Lubitz, MD, MPH, assistant professor, Massachusetts General Hospital, discusses the diagnosis of thyroid cancer.
Latest:
Effects of Para-aortic Lymph Node Metastases on Endometrial Cancer SurvivalCarrie L. Langstraat, MD, discusses how para-aortic lymph node metastases impact survival outcomes in patients with endometrial cancers.
Latest:
Interesting Research in the Endometrial Cancer SpaceCasey M. Cosgrove, MD, discusses research exploring precision medicine concepts for endometrial cancer treatment.
Latest:
Pregnancy Disproved as Potential Trigger for Relapse in Hodgkin Lymphoma SurvivorsResearchers discovered that pregnancy while in remission of Hodgkin lymphoma does not increase the risk of cancer relapse, making this report the first largest study to specifically examine the impacts of pregnancy as a potential trigger for relapse in Hodgkin lymphoma survivors.
Latest:
T Cell Resistance to TGF-Beta in LymphomaCatherine Bollard, MBChB, MD, from the Baylor College of Medicine, discusses T cells and TGF-beta in Hodgkin's lymphoma and Non-Hodgkin lymphoma.
Latest:
Questions on Genetic Counseling in the Community SettingCatherine Fine, MS, Certified Genetic Counselor, lead, Clinical Cancer Services at Genome Medical, discusses questions on genetic counseling in the community setting.
Latest:
Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular LymphomaCatherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).
Latest:
Clinical Trials Exploring Bevacizumab in NSCLCCatherine Shu, MD, medical oncologist, Division of Hematology/Oncology, Columbia University Medical Center, discusses two clinical trials exploring the use of bevacizumab (Avastin) in patients with non-small cell lung cancer.
Latest:
Biomarker Testing for Anal CancerCathy Eng, MD, discusses what can be done in order to integrate biomarker testing for anal cancer into clinical practice.
Latest:
Ongoing Clinical Trials in BRAF-Mutant CRCCathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.
Latest:
A Study Examining Breast Cancer Mortality Rates Across 47 CountriesCecile Pizot, a biostatistician in Epidemiology at the International Prevention Research Institute, discusses a study that examined breast cancer mortality rates across 47 countries.
Latest:
Using Immunotherapy for the Treatment of MelanomaCeleste Lebbé, MD, from the Hôpital Saint Louis, in Paris, France, discusses the use of immunotherapy for the treatment of melanoma.
Latest:
MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLCTwo presentations at this year’s American Association for Cancer Research (AACR) annual meeting linked a specific microRNA (miRNA), miR-34a, to an active area in immunotherapy, programed cell death-1 (PD-1) protein and its ligand, PD-L1.
Latest:
Hypogammaglobulinemia and Abiraterone Therapy for Metastatic Prostate CancerDescription of 3 cases whereby significant septic complications occurred in the setting of abiraterone use that were associated with hypogammaglobulinemia.
